Amarin Corp Plcuk AMRN
NASDAQ AMRN
$14.09 +0.03 (+0.21%)
At close: Aug 21, 2026 · 4:00 PM EDT

Amarin Corp Plcuk (AMRN) Cash & Equivalents (2010 - 2026)

Amarin Corp Plc\Uk (AMRN) posted quarterly Cash & Equivalents of $143.6 million for Q2 2026, down 2.91% year-over-year from $147.9 million in Q2 2025, and up 9.53% quarter-over-quarter from $131.1 million in Q1 2026.

Amarin Corp Plcuk (AMRN) Cash & Equivalents (2010 - 2026) Analysis & Trends

Amarin Corp Plc\Uk (AMRN) has reported Cash & Equivalents for 17 consecutive years, with $143.6 million the latest figure, recorded in Q2 2026.

  • In Q2 2026, Cash & Equivalents fell 2.91% year-over-year to $143.6 million; the TTM figure through Jun 2026 stood at $143.6 million (down 2.91% YoY), while the FY2025 annual figure was $134.7 million, up 11.25% from the prior year.
  • Cash & Equivalents advanced to $143.6 million in Q2 2026 per AMRN's latest filing, from $131.1 million in the prior quarter.
  • Across five years, Cash & Equivalents topped out at $270.8 million in Q3 2023 and bottomed at $119.5 million in Q1 2025.
  • Historically, Cash & Equivalents has averaged $183.7 million across 5 years, with a median of $195.3 million in 2023.
  • Annual changes were most pronounced in 2023 — Cash & Equivalents advanced 12.6% — and 2025, when it tumbled 44.13%.
  • Amarin Corp Plc\Uk's Cash & Equivalents stood at $217.7 million in 2022, then slipped by 8.46% to $199.3 million in 2023, then sank by 39.25% to $121.0 million in 2024, then advanced by 11.25% to $134.7 million in 2025, then gained by 6.64% to $143.6 million in 2026.
  • Business Quant data shows AMRN's Cash & Equivalents at $143.6 million in Q2 2026, $131.1 million in Q1 2026, and $134.7 million in Q4 2025.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Cash & Equiv. (Qtr)
1 Johnson & Johnson 652.20 Bn 631.44 Bn 17.26 Bn 20.42 Bn
2 AbbVie 469.51 Bn 462.94 Bn 12.70 Bn 6.57 Bn
3 Merck 376.81 Bn 369.67 Bn 12.21 Bn 6.85 Bn
4 Novartis Ag 303.04 Bn 295.35 Bn 11.24 Bn 7.62 Bn
5 Astrazeneca 257.61 Bn 252.71 Bn 12.86 Bn 4.90 Bn
6 Amgen 237.37 Bn 223.38 Bn 7.24 Bn 13.99 Bn
7 Gilead Sciences 181.73 Bn 178.55 Bn 6.22 Bn 3.18 Bn
8 Pfizer 159.66 Bn 147.96 Bn 10.94 Bn 976.00 Mn
9 Gsk 106.24 Bn 102.07 Bn 8.24 Bn 4.17 Bn
10 Amarin Corp Plcuk 5.86 Bn 5.54 Bn 14.99 Mn 143.60 Mn

Historic Data

Download Data
DateValue
Jun 30, 2026 143.60 Mn
Mar 31, 2026 131.10 Mn
Dec 31, 2025 134.66 Mn
Sep 30, 2025 122.80 Mn
Jun 30, 2025 147.90 Mn
Mar 31, 2025 119.52 Mn
Dec 31, 2024 121.04 Mn
Sep 30, 2024 156.94 Mn
Jun 30, 2024 215.92 Mn
Mar 31, 2024 213.94 Mn
Dec 31, 2023 199.25 Mn
Sep 30, 2023 270.81 Mn
Jun 30, 2023 233.00 Mn
Mar 31, 2023 191.41 Mn
Dec 31, 2022 217.67 Mn
Sep 30, 2022 240.50 Mn
Jun 30, 2022 228.00 Mn
Mar 31, 2022 219.20 Mn
Dec 31, 2021 219.45 Mn
Sep 30, 2021 222.90 Mn